FIXX Share Price | Homology Medicines, Inc. Stock Analysis & Recommendation

Q: How big is Homology Medicines, Inc.?

Market Cap: As of Jun 18, Homology Medicines, Inc. has a market capitalization of 19.73 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Homology Medicines, Inc. reported net sales of 0.00 million and a net profit of -59.79 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 5.67 million and total assets of 92.33 million.

Q: What does Homology Medicines, Inc. do?

Overview: Homology Medicines, Inc. is a genetic medicines company focused on developing gene editing and gene therapy treatments for rare diseases within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.Financial Snapshot: Most recent Net Profit: -11 Million (Quarterly Results - Mar 2025) Market cap: USD 19.73 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: 12.99 Return on Equity: 1,455.21% Price to Book: -4.92Contact Details: Address: 1 Patriots Park, BEDFORD MA: 01730-2343 Tel: 1 781 3017277 Fax: 1 302 6555049 Website: https://www.homologymedicines.com/

Q: Is Homology Medicines, Inc. overvalued or undervalued?

As of 9 February 2024, the valuation grade for Homology Medicines, Inc. has moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently assessed as overvalued, particularly given its negative price-to-book value of -5.77 and a high return on capital employed (ROCE) of 113.04%, which suggests inefficiencies in capital utilization despite high returns.In comparison to its peers, Homology Medicines shows a stark contrast with G1 Therapeutics, Inc. and ADC Therapeutics SA, both rated as risky with P/E ratios of -8.43 and -2.10, respectively. The EV to EBITDA ratio for Homology is 0.46, which is more favorable than some peers, but the overall financial health and performance metrics suggest that the stock is not justified at its current price of $1.53, especially considering its drastic underperformance against the S&P 500 over the past year, where it has declined by 90.12%.

Q: Is Homology Medicines, Inc. technically bullish or bearish?

As of 21 August 2025, the technical trend for Homology Medicines, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the weekly RSI is bearish, contrasting with a bullish monthly RSI, suggesting mixed signals across time frames. The daily moving averages are bearish, further supporting the mildly bearish stance. Additionally, the Bollinger Bands are bearish on a weekly basis and mildly bearish monthly. Overall, the stock has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -49.42% versus the S&P 500's 12.22%, and a one-year return of -96.25% compared to the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

60.52 k

Shareholding (Mar 2025)

FII

24.11%

Held by 41 FIIs

DII

Held by 17 DIIs

Promoter

60.47%

How big is Homology Medicines, Inc.?

22-Jun-2025

As of Jun 18, Homology Medicines, Inc. has a market capitalization of 19.73 million, with net sales of 0.00 million and a net profit of -59.79 million over the last four quarters. The company reported shareholder's funds of 5.67 million and total assets of 92.33 million as of Dec 24.

View full answer

What does Homology Medicines, Inc. do?

22-Jun-2025

Homology Medicines, Inc. is a micro-cap genetic medicines company focused on developing gene editing and gene therapy treatments for rare diseases. As of March 2025, it reported a net profit loss of $11 million and has a market cap of $19.73 million.

View full answer

Who are in the management team of Homology Medicines, Inc.?

22-Jun-2025

As of March 2022, the management team of Homology Medicines, Inc. is led by Dr. Arthur Tzianabos as President and CEO, alongside independent directors Mr. Jeffrey Poulton, Mr. Steven Gillis, Dr. Richard Gregory, Dr. Kush Parmar, and Mr. Matthew Patterson.

View full answer

Is Homology Medicines, Inc. overvalued or undervalued?

25-Jun-2025

As of February 9, 2024, Homology Medicines, Inc. is rated as "does not qualify" due to being overvalued at $1.53, with a negative price-to-book value of -5.77 and a significant decline of 90.12% against the S&P 500 over the past year, despite a high ROCE of 113.04%.

View full answer

Is Homology Medicines, Inc. technically bullish or bearish?

20-Sep-2025

As of August 21, 2025, Homology Medicines, Inc. shows a mildly bearish trend with mixed technical indicators, including mildly bullish MACD signals but bearish daily moving averages, and has significantly underperformed the S&P 500 with a year-to-date return of -49.42%.

View full answer

Compare Homology Medicines, Inc. with Similar Stocks

Eyenovia, Inc.Kinnate Biopharma, Inc.ADC Therapeutics SA

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 20 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

3.39

Return on Equity

411.30%

Price to Book

-1.66

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-9 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

63.29%

6 Months

100.52%

1 Year

18.71%

2 Years

-69.3%

3 Years

128.99%

4 Years

-94.56%

5 Years

-98.39%

Homology Medicines, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

9.52%

EBIT to Interest (avg)

-96.93

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

12.99

Sales to Capital Employed (avg)

0.02

Tax Ratio

0.04%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-5.77

EV to EBIT

0.46

EV to EBITDA

0.46

EV to Capital Employed

0.52

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

113.04%

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 20 Schemes (15.49%)

Foreign Institutions

Held by 41 Foreign Institutions (24.11%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 13.64% vs 22.54% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.10",
          "val2": "-12.10",
          "chgp": "24.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.60",
          "val2": "-1.50",
          "chgp": "60.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.50",
          "val2": "-11.00",
          "chgp": "13.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 100.00% vs -309.38% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 11.17% vs -974.00% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "-6.70",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-65.60",
          "val2": "-47.80",
          "chgp": "-37.24%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "1.50",
          "chgp": "-80.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "17.40",
          "val2": "-6.20",
          "chgp": "380.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-47.70",
          "val2": "-53.70",
          "chgp": "11.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-9.10

-12.10

24.79%

Interest

0.30

Exceptional Items

-0.60

-1.50

60.00%

Consolidate Net Profit

-9.50

-11.00

13.64%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 13.64% vs 22.54% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

-6.70

100.00%

Operating Profit (PBDIT) excl Other Income

-65.60

-47.80

-37.24%

Interest

0.30

1.50

-80.00%

Exceptional Items

17.40

-6.20

380.65%

Consolidate Net Profit

-47.70

-53.70

11.17%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 100.00% vs -309.38% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 11.17% vs -974.00% in Dec 2023

All Annual Results

Company CV

About Homology Medicines, Inc.

Homology Medicines, Inc.

Pharmaceuticals & Biotechnology

Homology Medicines, Inc. is a genetic medicines company translating gene editing and gene therapy technology into treatments for patients with rare diseases. The Company is focused on developing a pipeline of new medicines that address and cure the underlying cause of monogenic diseases in the liver, central nervous system (CNS), bone marrow, lung and the eye. The Company’s lead product candidate, HMI-102 is a gene therapy for the treatment of phenylketonuria (PKU). Its PKU program is focused on adults using the gene therapy approach. The Company’s suite of 15 adeno-associated virus vectors (AAVHSCs) enables it to focus on a method of gene editing called gene correction. The Company’s diverse set of AAVHSCs allows it to precisely target, via a single intravenous injection, a wide range of disease-relevant tissues, including the liver, central nervous system, or CNS, bone marrow, lung, muscle and eye, across both modalities - gene editing and gene therapy.

Company Coordinates

Company Details

1 Patriots Park , BEDFORD MA : 01730-2343

Tel: 1 781 3017277

https://www.homologymedicines.com/

Registrar Details

Homology Medicines, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Homology Medicines, Inc.?

Watch in Real-Time

What does Homology Medicines, Inc. do?

Who are in the management team of Homology Medicines, Inc.?

Is Homology Medicines, Inc. overvalued or undervalued?

Is Homology Medicines, Inc. technically bullish or bearish?

Compare Homology Medicines, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Homology Medicines, Inc.

Company Coordinates